ICML 2017 | Highlights from ICML 2017: The CLL2-BAG study

Barbara Eichhorst

Barbara Eichhorst, MD, from the University Hospital Cologne, Germany, discusses the CLL2-BAG trial from the German CLL study group (GCLLSG), in her opinion, one of the highlights from the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland. Looking at treatment naïve and relapsed chronic lymphocytic leukemia (CLL), patients received sequential treatment with bendamustine, obinutuzumab, and venetoclax. Results from this trial have been excellent, with patients responding well, experiencing good tolerability and showing high rates of minimal residual disease.

Share this video